RAPP Company Profile and Key Details

Rapport Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.88. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of -1.88% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $80.00 to $40.00. The high target offers 83.4% upside. The low target suggests -8.3% downside. The mean target is $53.93. This offers 23.64% upside. Rapport Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 23.56%. The prior quarter beat by 6.25%. Over the last six quarters, Apple has recorded several small beats. These include -13.79% in August 07, 2025.

Rapport Therapeutics, Inc. Common Stock has 47.98 million shares outstanding. The public float is 32.30 million shares, elevated short interest at 7.42% of float. This equals 2.25 million shares. The short ratio is 5.99 days. Institutional investors hold 114.87% of the float. Insiders own 4.6%. Third Rock Ventures V, L.P. holds 6.28 million shares, Ceesay Abraham has 458.98 thousand shares and Bredt David has 387.08 thousand shares. Over the past six months, insider transactions show net selling. They sold 976.64 thousand shares across 23 transactions.

Short-term trend indicators are mixed aligned (SMA20 4.7%, SMA50 3.78%, SMA200 35.88%). The stock’s 14-day RSI is 55.6 (neutral), while the ATR of 2.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -30.21% below its high and over 358.79% above its low. Average 10-day trading volume of 335.63 thousand shares is in line with the 3-month average of 350.35 thousand, indicating normal recent market interest.

Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) closed at $43.62 USD, gaining $0.16 (0.37%) from the previous close of $43.46. The stock is currently mid-range between its 52-week high and low $22.73 and $52.93. With a market capitalization of about $2.09 billion, Rapport Therapeutics, Inc. Common Stock is classified as a mid-cap and shows market-like volatility (beta ~1.03). Key stats such as the average daily volume over the past year has been around 352.05 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Rapport Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Abraham N. Ceesay, the company employs approximately 84 people and listed since June 07, 2024. Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders.

Rapport Therapeutics, Inc. Common Stock trades at a P/E ratio of -14.31, slightly below the S&P 500 average, with a price-to-sales ratio of 104.04 and a price-to-book ratio of 4.88 trading at moderately above to book value. The P/FCF stands at -21.42, also below market averages.

Our AI price prediction model suggests that Rapport Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.6%, with price expected at $38.56 by September 25, 2026, within a range of $36.85 to $40.19 3-Month Outlook: Projected rise of 70.15%, reaching $74.22 by December 10, 2026, with a range of $72.01 to $76.71. 1-Year Outlook: Projected gain of 22.56%, with price at $53.46 by September 10, 2027, within a range of $50.91 to $56.47.

Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) shares are down -14.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Rapport Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -14.31. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $47.62, suggesting 9.17% upside. Our AI forecast model points to short-term weakness (-11.6% over two weeks), a medium-term rise (70.15% over three months), and a longer-term gain (22.56% over one year), with expected trading ranges indicating moderate volatility.